Benign Prostatic Hyperplasia Therapeutics Market By Top Key Players of Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH, Eli Lilly & Company And Many Others
The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4708
Benign prostatic hyperplasia (BPH) is a medical condition in which a males prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.
Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.
The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.
The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.
Get More Information @ https://www.alliedmarketresearch.com/connect-to-analyst/4708
North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017, and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.
The key players of the global benign prostatic hyperplasia therapeutics market include
• Abbott Laboratories,
• Allergan plc,
• Astellas Pharma, Inc.,
• Boehringer Ingelheim Pharma GmbH & Co. KG,
• Eli Lilly and Company,
• GlaxoSmithKline plc,
• Merck & Co., Inc.,
• Pfizer, Inc.,
• Sanofi, and
• Teva Pharmaceutical Industries Limited.
Table Of Content
Chapter: 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Chapter: 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porter’s Five Forces analysis
3.4.1. Bargaining power of buyers
3.4.2. Bargaining power of suppliers
3.4.3. Threat of substitution
3.4.4. Threat of new entrant
3.4.5. Competitive rivalry
3.5. Market dynamics
126.96.36.199. Rise in in geriatric population
188.8.131.52. Rise in prevalence of benign prostatic hyperplasia
184.108.40.206. Growth in the awareness related to urological disorders and prostate cancer
220.127.116.11. High preferences for minimally invasive surgical therapies
18.104.22.168. Large number of products in pipeline
22.214.171.124. Opportunities in emerging economies
3.5.4. Impact analyses
3.6. Clinical trials
Access Full Summery @ https://www.alliedmarketresearch.com/press-release/benign-prostatic-hyperplasia-therapeutics-market.html
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Benign Prostatic Hyperplasia Therapeutics Market By Top Key Players of Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH, Eli Lilly & Company And Many Others here
News-ID: 1600776 • Views: 299
More Releases from Allied Market Research
North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently
More Releases for Benign
Global Benign Prostatic Hyperplasia Treatment Devices Market Outlook 2018-2025 K …
A detailed market study on "Global Benign Prostatic Hyperplasia (BPH) Treatment Devices Market" examines the performance of the Benign Prostatic Hyperplasia (BPH) Treatment Devices market. It encloses an in-depth Research of the Benign Prostatic Hyperplasia (BPH) Treatment Devices market state and the competitive landscape globally. This report analyzes the potential of Benign Prostatic Hyperplasia (BPH) Treatment Devices market in the present and the future prospects from various angles in detail. The
Benign Positional Vertigo Market by Type - Benign, Paroxysmal, Positional and Ve …
The Global Benign Positional Vertigo Market is growing at the CAGR of ~4.0% during the forecast period and expected to reach US$ 797.3 million by 2023. Benign Positional Vertigo Market Segments: Worldwide Benign Positional Vertigo Market has been segmented on the basis of type which Benign, Paroxysmal, Positional, Vertigo, and others. On the basis of diagnosis, it is segmented into Electroencephalogram (EEG), Electronystagmography (ENG), Head CT, Head MRI, Hearing test, Magnetic resonance
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasma—ordinarily known as the fourth condition of issue—which has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded. Cold plasma isn't in
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports. This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices. Topics Covered Include: An overview of device-based and pharmacological therapies for BPH and prostatitis. Global and country/region-specific market forecasts, including forecasts by product segment. Competitive analyses
Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2 …
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746 Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a